NCT04405466 is a clinical trial of Blood sampling in COVID-19, sponsored by Miltenyi Biomedicine GmbH.

Who is sponsoring NCT04405466?

NCT04405466 is sponsored by Miltenyi Biomedicine GmbH.

What drugs are being tested in NCT04405466?

Interventions in NCT04405466: Blood sampling, Throat swab.

Is NCT04405466 still recruiting?

NCT04405466 is currently completed. Last updated 25 May 2022.

Last reviewed 2022-05-25 · How we verify

NCT04405466

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers

Completed Last updated 25 May 2022

What this trial tests

trial testing Blood sampling in COVID-19 in 417 participants. Completed in 17 December 2020.

Timeline

22 April 2020

Primary endpoint
5 November 2020

17 December 2020

Quick facts

Lead sponsor	Miltenyi Biomedicine GmbH
Status	Completed
Study type	OBSERVATIONAL
Enrollment	417
Start date	22 April 2020
Primary completion	5 November 2020
Estimated completion	17 December 2020
Sites	1 location across Germany

Drugs / interventions tested

Blood sampling — full drug profile →
Throat swab

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Miltenyi Biomedicine GmbH — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at baseline, day 21 and day 40.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood sampling

Trials testing the same drug.

NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
NCT07237984 — Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway · not yet recruiting
NCT06544018 — Circadian Rhythm Deregulation in Patients With CAPS · NA · recruiting
NCT07245550 — Thyroid and Adrenal Disorders in ICU · not yet recruiting
NCT07033091 — Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening · NA · recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Miltenyi Biomedicine GmbH trials

Trials by the same sponsor.

NCT06225050 — M-2018-334 in Hematological Malignancies · NA · not yet recruiting
NCT07178431 — MB-CART2019.1 in Refractory Multiple Sclerosis · Phase 1, PHASE2 · not yet recruiting
NCT07288879 — DALY II Japan/MB-CART2019.1 for DLBCL · Phase 2 · recruiting
NCT06508931 — Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms · Phase 2 · recruiting
NCT06189157 — MB-CART19.1 in Refractory SLE · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04405466 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Miltenyi Biomedicine GmbH
Last refreshed: 25 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04405466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing